Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

HTTPS

Secure .gov websites use HTTPS
A lock (LockA locked padlock) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

  • About HHS
  • MAHA in Action
  • Programs & Services
  • Grants & Contracts
  • Laws & Regulations
  • Radical Transparency
Breadcrumb
  1. Home
  2. Press Room
  3. HHS, FDA to Require Full Safety Disclosures in Drug Ads
  • Press Room
  • HHS Live
FOR IMMEDIATE RELEASE
September 9, 2025
Contact: HHS Press Office
202-690-6343
Submit a Request for Comment

HHS, FDA to Require Full Safety Disclosures in Drug Ads

WASHINGTON—SEPTEMBER 9, 2025—The U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) today announced a major reform of pharmaceutical advertisements that will require drug companies to include full safety warnings during their direct-to-consumer ads. Since 1997, an FDA loophole has allowed them to merely footnote vital information such as full contraindications and common precautions via webpages and 1-800 toll-free numbers.

The proliferation of simplistic pharmaceutical ads on television and digital media distorted physician prescribing habits and patient decisions. Research during this time found that:

  • Direct-to-consumer advertising drove about 31% of the rise in U.S. drug spending since 1997, when the FDA relaxed ad restrictions.
  • Patients who asked physicians for a direct-to-consumer advertised drug were about 17 times more likely to receive a prescription than those who didn't.
  • Seeing statin ads even briefly made low-risk patients 16% to 22% more likely to start taking the drugs.
  • 91% of direct-to-consumer drug ad claims featured social approval as a result of product use and 94% employed positive emotional appeals.

"Pharmaceutical ads hooked this country on prescription drugs," Health and Human Services Secretary Robert F. Kennedy, Jr. said. "We will shut down that pipeline of deception and require drug companies to disclose all critical safety facts in their advertising. Only radical transparency will break the cycle of overmedicalization that drives America's chronic disease epidemic."

"For far too long, the FDA has permitted misleading drug advertisements, distorting the doctor-patient relationship and creating increased demand for medications regardless of clinical appropriateness," said FDA Commissioner Marty Makary, M.D., M.P.H. "Drug companies spend up to 25% of their budget on advertising. Those billions of dollars would be better spent on lowering drug prices for everyday Americans."

Until 1997, pharmaceutical ads were required to report full contraindications, boxed warnings, and common precautions in advertisements. The FDA at that point established a loophole that allowed companies to recite a vague “major-risk statement” and then point viewers to a website, toll-free number, or print insert for more complete information. The FDA’s return to the pre-loophole status quo requires drug advertisers to present factual, uncontroversial statements that are already legally mandated and avoids undue burdens by preserving advertisers' rights to continue to engage in commercial speech.

Read President Trump’s memorandum addressing misleading direct-to-consumer prescription drug advertisements and the FDA’s fact sheet.

###
Note: All HHS press releases, fact sheets and other news materials are available in our Press Room.
Like HHS on Facebook, follow HHS on X @HHSgov, @SecKennedy, and sign up for HHS Email Updates.
Last revised: September 9, 2025

Submit a request for comment

For media inquiries, please submit a request for comment.

Sign up to receive our press releases

Sign Up

Related Press Releases

  • Americans to Gain New Access to Real-Time Prescription Drug Price Information

    • September 2, 2025 Press Release
  • FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers

    • July 29, 2025 Press Release
Content created by Assistant Secretary for Public Affairs (ASPA)
Content last reviewed September 9, 2025
Back to top
Secretary Robert F. Kennedy Jr.

Follow @SecKennedy

HHS icon

Follow @HHSGov

HHS Email updates

Receive email updates from HHS.

Subscribe

HHS Logo

HHS Headquarters

200 Independence Avenue, S.W.
Washington, D.C. 20201
Toll Free Call Center: 1-877-696-6775​

  • Contact HHS
  • Careers
  • HHS FAQs
  • Nondiscrimination Notice
  • Press Room
  • HHS Archive
  • Accessibility Statement
  • Privacy Policy
  • Budget/Performance
  • Inspector General
  • Web Site Disclaimers
  • EEO/No Fear Act
  • FOIA
  • The White House
  • USA.gov
  • Vulnerability Disclosure Policy